Drug intelligence / Profile preview

leucovorin + methotrexate + tegafur

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This combination involves **leucovorin**, a folate analog used to counteract the toxic effects of methotrexate; **methotrexate**, a dihydrofolate reductase inhibitor used in cancer treatment; and **tegafur**, a prodrug of fluorouracil used in cancer therapy. The combination is used for treating cancers, particularly in cases where high-dose methotrexate is used, and for enhancing the efficacy of fluorouracil derivatives like tegafur.

Other names: MUL (Methotrexate, Uracil, and Tegafur with Leucovorin)

Targets

DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)

Beyond the preview

Go deeper on leucovorin + methotrexate + tegafur.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on leucovorin + methotrexate + tegafur.

Explore the full profile